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Background
Gout is a painful arthritis associated with high serum
urate levels (hyperuricaemia) and subsequent crystal
deposition in joints. Although not all people with
Asymptomatic Hyperuricaemia (AH) develop gout, crys-
tal deposition and sub-clinical joint damage have been
observed in this population. Gout most commonly
affects the first metatarsophalangeal joint (1MTP). Exist-
ing theories suggest this may be related to the structure
and functional role of the joint during gait, yet such
characteristics of the 1MTP have not been investigated
in people with gout or with AH. The objective of this
study was to identify 1MTP characteristics in these peo-
ple by comparing them with normouricaemic controls.
Methods
Eighty-eight males (gout, n = 25; AH, n = 29; controls, n =
34) participated in this cross-sectional study. Primary out-
come measures were 1MTP pain and passive 1MTP dorsi-
flexion. Secondary outcome measures were foot-related
pain and disability and gait velocity. Exploratory outcome
measures included additional patient-reported outcomes
(general pain, patient global assessment, activity limitation
and lower limb function), 1MTP plantarflexion and dorsi-
flexion muscle strength, hallux valgus severity, Foot
Posture Index, 1MTP temperature, vibration perception
threshold, plantar protective sensation and dynamic
plantar pressure distribution (peak pressure and pressure
time integral).
Results
Compared to controls, people with gout had significantly
reduced 1MTP dorsiflexion (p<0.0001), greater foot-related
pain and disability (p<0.0001), reduced gait velocity
(p=0.024), greater activity limitation (p=0.008), reduced
lower limb function during activities of daily living
(p=0.010) and recreational activities (p<0.0001), higher
1MTP plantar and dorsal temperature (p=0.033 and 0.034,
respectively) and greater midfoot peak pressure and
pressure time integrals (p<0.0001). Compared to controls,
people with AH had significantly reduced lower limb func-
tion during recreational activities (p=0.033), higher Foot
Posture Index (p=0.035), greater midfoot peak pressure and
pressure time integral (p=0.001 and 0.002, respectively),
greater first metatarsal peak pressure (p=0.029) and greater
heel pressure time integrals (p=0.042).
Conclusions
Gout negatively impacts foot-related patient-reported out-
comes and is associated with impaired 1MTP function.
The presence of hyperuricaemia in the absence of sympto-
matic gout is also associated with reduced lower limb
function and may influence foot function during gait.
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